AQR Arbitrage’s Emergent Biosolutions EBS Stock Holding History

AQR Arbitrage’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,376	Closed	-$213K	–	1096
2020 Q4	$213K	Buy	+2,376	New	+$218K	0.01%	946

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Arbitrage's EBS Position: Q1 2021 in Review

AQR Arbitrage sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 2,376 shares — an estimated $213K sold.

AQR Arbitrage first reported a position in EBS in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

AQR Arbitrage reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
AQR Arbitrage sold 2,376 Emergent Biosolutions shares in Q1 2021, an estimated $213K.
AQR Arbitrage first reported a position in Emergent Biosolutions in Q4 2020 and held it in 1 quarter.
AQR Arbitrage's Emergent Biosolutions position peaked at $213K in Q4 2020.
340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on AQR Arbitrage's 13F filing for Q1 2021, filed 17 May 2021.